EarliPoint Health receives expanded FDA clearance for autism assessment in children up to age 8.

Read Release →

What Earns a Pediatrician’s Referral for Autism Evaluation

On This Page

The autism diagnostic environment has matured, changing how pediatric practices think about referrals. Where once there were one or two specialty centers to send a child to, pediatric practices in many regions now have a real set of choices: hospital-based specialty clinics, university-affiliated developmental centers, private psychology practices, and ABA practices offering diagnostic evaluation as part of an integrated service line.

The result is that the referral decision is no longer automatic. Pediatricians are evaluating diagnostic providers the same way they evaluate other specialty referrals, which means the choice is made based on a specific set of criteria that not every provider competing for those referrals fully understands.

This piece looks at what those criteria are. The audience is ABA practices, diagnostic groups, and developmental clinics seeking pediatrician referrals. The frame is observational, drawn from what referring physicians describe as the factors that shape who they keep sending patients to.

Why the Referral Decision Matters More Than It Used To

A meaningful share of operational risk in pediatric practice lies in the referral pathway. A positive autism screen creates a chain of obligations that extends well beyond the original visit. The family needs to be connected to the evaluation. The evaluation needs to occur. The report needs to come back. The next step (typically early intervention or an ABA referral) needs to be initiated. And the pediatrician’s chart needs to reflect what happened so subsequent well-child visits can be informed.

When that chain works, the pediatrician’s screening program produces what it’s designed to produce: earlier identification leading to earlier intervention. When it doesn’t, positive screens convert into open referral loops that quietly close themselves when families disengage from a process they find frustrating.

The choice of referral partner determines which of those two outcomes the pediatric practice experiences most often. That’s what makes the decision more consequential than the average referral.

The Factors Pediatric Practices Evaluate

Conversations with pediatricians, family medicine providers, and developmental screening clinicians consistently surface a similar set of decision criteria. Different practices weight them differently, but the underlying factors don’t vary much.

Turnaround Time

The variable families actually experience. The number that matters most is not “time from referral to evaluation” but “time from referral to written report in the pediatrician’s hands.” A practice that completes the evaluation in two weeks but takes six weeks to deliver the report is operating on a six-week cycle from the referring physician’s perspective.

Regional norms in many parts of the country sit at months. Pediatric practices comparing options notice quickly which providers operate meaningfully faster, and that difference shapes their referral pattern over time.

Report Quality and Structure

A diagnostic report serves several audiences at once: the family, the pediatrician’s chart, the downstream treatment team, and the insurance authorization process. A well-structured report supports all four. A vague one creates downstream problems in each of them.

The clearest test of report quality from a pediatric practice perspective is whether the diagnostic conclusion, supporting evidence, and recommended next steps can be found in a brief scan. Reports that bury those elements add friction to every subsequent chart review.

Family Experience During Evaluation

How the family is treated during the evaluation process affects everything downstream. Families who feel rushed or confused are less likely to engage with the recommended intervention pathway. Families who feel heard and supported are more likely to follow through. Pediatric practices that hear consistent feedback from families about a particular diagnostic provider tend to weight that input significantly.

Clinical Credibility

The diagnosis has to hold up. That means evaluators with appropriate credentials, the use of validated assessment tools, and alignment with current diagnostic standards. The field is increasingly incorporating objective, structured assessment alongside clinical interview. The EarliPoint System is one example of FDA-cleared, evidence-based technology being used in the assessment process. It aids qualified clinicians in the diagnosis and assessment of ASD in children 16 to 95 months old who are at risk based on concerns from a parent, caregiver, or healthcare provider. Practices that use validated, evidence-based tools alongside clinical judgment signal a different level of clinical rigor to referring physicians.

Communication Back to the Referring Practice

The referral isn’t complete when the evaluation happens. From the referring pediatrician’s perspective, it’s complete when the report has been delivered, the diagnosis has been communicated, and the family is on a clear path forward. Closed-loop referral systems remain inconsistently implemented across the field, but pediatric practices increasingly evaluate diagnostic partners on this dimension specifically. The provider that confirms receipt within a defined window, schedules within an agreed timeframe, and delivers a clean clinical summary back to the pediatric chart operates differently from one that sends a report whenever it’s done.

Insurance Accessibility

The criterion most often underweighted in conversations about diagnostic partners, and one that materially shapes which families can access the partner’s services at all. Practices that accept a narrow payer mix, or don’t accept Medicaid, create access gaps that the referring pediatrician then has to manage on the family’s behalf. Pediatric practices serving diverse patient populations weight insurance accessibility significantly when choosing referral partners.

What Separates the Practices That Earn Consistent Referrals

  • They publish their typical turnaround time honestly. Families and referring physicians can both see what the cycle looks like, not the best-case scenario.
  • They share sample reports with prospective referring practices. The format of the diagnostic report is clear, structured, and built for the pediatric chart workflow rather than the report writer’s preference.
  • They treat family experience as a deliberate operational priority rather than a soft factor. Trained intake staff. Clear pre-visit communication. A structured feedback session at the end of evaluation. None of this is exotic. Most diagnostic providers don’t do it consistently.
  • They build closed-loop reporting infrastructure with their pediatric partners. Named contact on each side. Defined communication cadence. Report delivery within an agreed window. Confirmation receipts. The closer that infrastructure resembles a well-run B2B account management relationship, the more reliable the referral flow becomes.
  • They handle insurance work as part of the service. Families don’t have to figure out coverage themselves. Prior authorization is managed proactively. Out-of-pocket costs are communicated upfront.

Closing Thoughts

The competition for pediatric autism referrals isn’t typically won by being clinically excellent. Most credible diagnostic providers are clinically credible. It’s won by being operationally consistent: predictable on turnaround, clear on communication, accessible across payer types, and reliable on the report side. The pediatric partners that send the most referrals tend to be the ones whose referral relationships have been treated as partnerships rather than transactions.

For diagnostic providers and ABA practices considering how technology-assisted assessment supports faster, more structured evaluation, our provider network team is a useful starting point.

Pete Polgar

VP of Marketing

Pete Polgar is the Vice President of Marketing at Earlipoint. He leads the company’s marketing strategy, focusing on brand positioning, demand generation, and digital growth. With a background in performance marketing and content strategy, Pete works on aligning marketing initiatives with business development to drive measurable results and expand Earlipoint’s market presence.

Pete Polgar

VP of Marketing

Pete leads EarliPoint’s marketing strategy — driving brand growth, demand generation, and measurable business results.

See how EarliPoint fits seamlessly into your clinical workflow.

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder